Novo Nordisk today presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions, in Chicago, US. In the STEP UP trial, semaglutide 7.2 mg, the higher dose of Wegovy® demonstrated a mean weight loss
